The International Olympic Committee (IOC) Consensus Statement on Periodic Health Evaluation of Elite Athletes, March 2009

Abstract

INTRODUCTION The Olympic Games is the largest sport event in the world. In Beijing, 10,500 athletes competed, selected from a large group of elite athletes in 204 countries. Sports participation on the elite level, aside from winning medals, fame and other rewards, is also important from a health perspective. There is no longer any doubt that regular physical activity reduces the risk of premature mortality in general, and of coronary heart disease, hypertension, colon cancer, obesity, and diabetes mellitus in particular. The question is whether the health benefits of sports participation outweigh the risk of injury and long-term disability, especially in high-level athletes.1 have studied the incidence of chronic disease and life expectancy of former male world-class athletes from Finland in endurance sports, power sports and team sports. The overall life expectancy was longer in the high-level athlete compared to a reference group (75.6 vs 69.9 years). The same group also showed that the rate of hospitalization later in life was lower for endurance sports and power sports compared to the reference group.2 This resulted from a lower rate of hospital care for heart disease, respiratory disease and cancer. However, the athletes were more likely to have been hospitalized for musculoskeletal disorders. Thus, the evidence suggests that although there is a general health benefit from sports participation, injuries represent a significant side effect. One priority of the International Olympic Committee (IOC) is to protect the health of the athlete. During recent years, prevention of injuries and illnesses has been high on the IOC agenda. During the Athens Games an injury surveillance system was applied for all team sports.3 During the Beijing Games, the IOC ran, for the first time, an injury surveillance system covering all the athletes, showing a 10% incidence of injuries.4 In Vancouver and London the surveillance system will include disease conditions as well. The surveillance studies are prerequisites for providing evidence for health development in sports as well as for developing prevention programs. Another method to decrease injuries and diseases in the elite athlete is to perform a pre-participation examination (PPE) or periodic health evaluation (PHE) of all elite athletes.5 PHE in various forms have been available for many years, but a recent analyses5 has questioned the efficacy of PHEs in detecting serious problems in the elite athlete. In March 2009, the IOC assembled an expert group to discuss the current state of health evaluations for athletes, aiming to provide recommendations for a practical PHE for the elite athlete, as well as to outline the need for further research. The task of the group was to review the benefits as well as potential negative effects of PHE at the elite sport level. The group did not take any position as to whether PHE should be recommended as compulsory for participation in sport. That is for the relevant sports authorities to decide. The PHE can serve many purposes. It includes a comprehensive assessment of the athlete's current health status and risk of future injury or disease and, typically, is the entry point for medical care of the athlete. The PHE also serves as a tool for continuous health monitoring in athletes. Recent advances in this field relate to: (1) data on sudden cardiac death and other noncardiac medical problems, and the detection of risk factors and groups; (2) a consensus conference on concussion; (3) data on eating disorders; and (4) data on risk factors for musculoskeletal injuries. This paper addresses each of these advances in more detail after a discussion on the purpose of a PHE and the evidence we have supporting the different components of the PHE. PURPOSES OF THE MEDICAL EVALUATION In a narrow sense, the main purpose of the PHE is to screen for injuries or medical conditions that may place an athlete at risk for safe participation. Athletes may be affected by conditions that do not have overt symptoms and that can only be detected by periodic health evaluations. One example is cardiovascular abnormalities, such as hypertrophic cardiomyopathy, arrythmogenic right ventricular cardiomyopathy or congenital coronary arteries anomalies. These are typically silent until a potentially fatal arrhythmia occurs, but may in some cases be detected through a careful cardiovascular examination. Screening is a strategy used in a population to detect a disease in individuals without signs or symptoms of that disease. The intention is to identify pathologic conditions early, thus enabling earlier intervention and management in the hope of reducing future morbidity and mortality. Although screening may lead to an earlier diagnosis, not all screening programs have been shown to benefit the person being screened. To ensure that screening programs confer the intended benefit, the World Health Organisation published what have become known as the Wilson-Jungner criteria for appraising a screening programme.6 The main criteria are that the condition being screened for is an important health problem (depends not just on how serious the condition is, but also how common it is), that there is a detectable early stage, that treatment at an early stage is of more benefit than at a later stage and that a suitable test is available to detect disease in the early stage. From a public health perspective, there is insufficient evidence to date to mandate any specific screening tests for elite athletes apart from those recommended for the general population. This is mainly the consequence of the low risk of serious conditions in this population. An important limitation is also the lack of suitable screening tests; such tests must be reliable (repeatable, good inter-observer agreement), sensitive (detects all those with increased risk), specific (detects only those with increased risk), affordable (ideally cheap, easy to perform, widely available), acceptable to the screening population and subject to quality assurance. However, the PHE may serve other purposes than just screening athletes for future health problems. One obvious goal is to ensure that current health problems are managed appropriately and, ultimately, to determine whether an athlete is medically suitable to engage in a particular sport or event. Even elite athletes with easy access to medical care do not always seek medical attention for injuries or disease, despite having significant symptoms. Some silent conditions are common and, although not severe from a health perspective, may influence sports performance. An example of this is mild iron deficiency, which is common in female athletes. Periodic health evaluations and ongoing monitoring represent an opportunity to diagnose and manage such conditions. They also provide an opportunity to identify conditions that are barriers to performance. An example is astigmatism, which can be detected on a simple test of visual acuity. Another important function of PHEs is that they allow the athlete an opportunity to establish a relationship with the health personnel who will be involved in providing continuing care. Finally, the PHE also represents an opportunity to look for characteristics which may put the elite athlete at risk for future injury or disease. However, as mentioned above, there is limited direct evidence to suggest that it is possible to predict future outcomes based on the PHE. Nevertheless, there is evidence in some areas, such as injury risk factor assessment,7 that holds future promise and warrants investigation related to the PHE. Depending on the sport and the age, ethnic origin and gender of the athlete, it may be prudent to include an assessment of specific risk factors in the PHE. GENERAL REQUIREMENTS OF A PHE It is important to address and balance the ethical and legal aspects of the PHE in order to help protect the rights and responsibilities of athletes, physicians, sporting organizations and other persons concerned. In the context of designing and implementing a PHE, the following considerations need to be taken into account: PHE should be based on sound scientific and medical criteria PHE should be performed in the primary interest of the athlete, that is, assessing his/her health in relation to his/her practice of a given sport PHE should be performed under the responsibility of a physician trained in sports medicine, preferably by the physician responsible for providing ongoing medical care for the athlete, for example, the team physician The decision concerning the nature and scope of the PHE should take into account individual factors, such as the geographical region, the sport discipline, the level of competition, age and gender of the athlete The setting of the evaluation should be chosen to optimize the accuracy of the examination and respect the privacy of the athlete. The PHE should preferably be carried out in the physician's office, which assures privacy, access to prior medical records, and an appropriate patient-physician relationship A physician can only perform a PHE with the free and informed consent of the athlete and, if applicable, his/her legal guardian If PHE evidences that an athlete is at serious medical risk, the physician must strongly discourage the athlete from continuing training or competing until the necessary medical measures have been taken Based on such advice, it is the responsibility of the athlete to decide whether to continue training or competing If a physician is requested to issue a medical certificate, he or she must have explained in advance to the athlete the reason for the PHE and its outcome, as well as the nature of information provided to the third parties. In principle, the medical certificate may only indicate the athlete's fitness or unfitness to participate in training or competition and should minimize disclosure of confidential medical information In many settings, the PHE is used to offer medical clearance to participate in sport and is seen as a 1-time certification for future involvement in elite sport. However, the evaluation of the athlete's health should ideally be seen as a dynamic, ongoing process. While many aspects of the PHE will be common to all elite athletes, it should be tailored to be gender, age, race, culture and sport specific when appropriate. If any injury or medical condition is identified, it should be managed in a manner consistent with the existing standards of medical care. If warranted, this may involve referral to the appropriate specialists for further evaluation and management. It should be noted that the PHE is also the time that medications or nutritional products in use or prescribed should be reviewed to determine if a Therapeutic Use Exemption (TUE) application to the World Anti-Doping Association (WADA) is needed. The timing of the PHE should ideally allow for sufficient time for management of any injuries or medical problems well before major competitions. For example, it is preferable to conduct a PHE during the off-season so that rehabilitation or other treatment can restore the athlete to optimal health before facing maximal physical stress. As the PHE is the only contact that many elite athletes will have with medical personnel, it should be seen as an opportunity for education regarding other health risks and health-related behavior. The following document is laid out in sections that correspond to the various areas of evaluation appropriate to the elite athlete. 1. CARDIOLOGY 1.1 Introduction The scope of the cardiovascular PHE is to detect potentially lethal cardiovascular disease in elite athletes and start appropriate management to reduce the risk for sudden cardiac death and/or disease progression in a timely fashion. 1.2 Evidence Base 1.2.1 Cardiovascular (CV) Risk of Competitive Sport Participation Regular participation in training and athletic competition is associated with an increased risk for sudden cardiac death (SCD), with an average relative risk for athletes of 2.8 times compared to their nonathletic counterpart.8 It is worthy to note, however, that sport is not per se the cause for greater incidence of SCD. It is the combination of intensive physical exercise in athletes with underlying cardiovascular disease, which can trigger ominous arrhythmias leading to cardiac arrest. The relative risk of sport participation is different according to the underlying disease, and it is greatest in case of cardiomyopathies (such as hypertrophic cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy) or congenital coronary arteries anomalies.8 1.2.2 Rationale for CV Evaluation in Elite Competitive Athletes The vast majority of the athletes dying suddenly do not experience premonitory symptoms9; therefore, the PHE represents the only strategy capable to identify athletes with silent cardiac disease, and allow appropriate management to reduce the risk of SCD and disease progression. Identifying asymptomatic athletes with underlying cardiovascular disease through the PHE is important because SCD could be prevented by lifestyle modification, including (when necessary) restriction from competitive sports activity, but also prophylactic treatment by drugs, implantable cardioverter defibrillator (ICD) or other therapeutic options. Athletes carrying an increased cardiac risk may have a favourable long-term outcome thanks to timely identification and appropriate clinical management.10 1.2.3 Rationale for Including the 12-Lead Electrocardiogram (ECG) in the PHE Recent scientific evidence supports the role of ECG in reducing mortality in screened athletes.11 This concept is based on the recognition that ECG is abnormal in most individuals with hypertrophic cardiomyopathy (up to 90%) and arrhythmogenic right ventricular cardiomyopathy (up to 80%). The ECG can also identify athletes with Wolff-Parkinson-White syndrome and ion channel diseases, such as Lènegre conduction disease, long or short QT syndromes, and Brugada syndrome,12,13 However, there has been criticism voiced related to available data on the use of ECG in the elite athlete based on lack of an unscreened athletic control group. A comparison of athletes screened with ECG versus athletes non-screened will require 2 matched large athlete populations (several thousand athletes, in consideration of the low incidence of cardiomyopathies) undergoing long-term follow-up (at least 2 decades, due to the young age of athletes at initial evaluation). It has been demonstrated that adding a 12-lead ECG examination to history and physical examination results in a substantial increase in the ability to identify potentially lethal heart disorders12,13 and this strategy has been endorsed in “The Lausanne Recommendations”14 and the European Society of Cardiology recommendations.15 However, it is not currently recommended by the American Heart Association.16,17 1.3 Proposal for PHE The following questions regarding cardiovascular abnormalities should be included: 1.3.1 Family History Family history of 1 or more relatives with disability or death of heart disease (sudden/unexpected) before age 50 Family history of cardiomyopathy, coronary artery disease, Marfan syndrome, long QT syndrome, severe arrhythmias, or other disabling cardiovascular disease 1.3.2 Personal History Syncope or near-syncope Exertional chest pain or discomfort Shortness of breath or fatigue out of proportion to the degree of physical effort Palpitations or irregular heartbeat Physical examination should be performed according to the best clinical care and should investigate the presence of: Musculoskeletal and ocular features suggestive of Marfan syndrome Diminished and delayed femoral artery pulses Mid- or end-systolic clicks Abnormal second heart sound (single or widely split and fixed with respiration) Heart murmurs (systolic grade >2/6 and any diastolic) Irregular heart rhythm Brachial, bilateral blood pressure >140/90 mm Hg on more than 1 reading 1.3.3 The 12-Lead ECG The 12-lead ECG should be recorded on a non-training day, during rest, according to best clinical practice. Interpretation of the ECG abnormalities can be categorized according to the criteria defined by Corrado et al18 into 2 groups: (1) the most common in trained athletes (sinus bradycardia, first degree AV block, notched QRS in V1 or incomplete right bundle branch block, isolated QRS voltage criteria for LV hypertrophy) consistent with athlete's age, ethnical origin and level of athletic conditioning, and that do not require additional testing; (2) all other less common ECG abnormalities should be further evaluated to exclude cardiovascular disease (Figure 1).FIGURE 1: Twelve lead ECG abnormalities.1.3.4 Further Investigations At present, there is no agreement regarding the need for routine use of echocardiography in the PHE. Neither is there a role for routine use of other imaging or invasive testing. However, in the presence of abnormal findings either at history, physical examination or 12-lead ECG, additional testing should be performed in order to confirm (or exclude) cardiovascular disease. In most instances, echocardiography is the first-line test, but other imaging modalities (such as cardiac magnetic resonance) or invasive testing, when necessary, may be pursued. In adult athletes (> 35 years) exercise ECG testing in the context of PHE is efficient to detect otherwise unsuspected cardiac abnormalities19 and is currently recommended for elite athletes with increased cardiovascular risk profile.20 1.4 Management of Athletes with CV Abnormalities The IOC PHE Consensus Group recommends that any athlete identified with a CV abnormality should be managed according to the current, widely accepted clinical recommendations, that is, Bethesda Conference #36 and ESC recommendations15,21,22. The group acknowledges that identification of cardiac disease in an athlete represents a challenging question regarding the ethical, medical and legal consequence with particular regard to the need for disqualification from competition. However, there is scientific evidence that preventing athletes with specific cardiovascular abnormality from regular training and competition is an efficient strategy for preventing SCD.10,23 Unnecessary exclusion from participation of competitive athletes with non-lethal diseases is a problem. Therefore, there is a need for a common agreement of sports eligibility guidelines and management of competitive athletes with cardiovascular diseases in the future.24 The main goal should be to reduce the number of unnecessary disqualifications and to adapt (rather than restrict) sports activity in relation to the specific cardiovascular risk. Finally, we recognize that young competitive athletes (<18 years) require specific expertise in the evaluation, interpretation of findings and management. 1.5 Educational Programmes The sport organizations together with scientific sport societies should encourage and support educational activities intended to enhance the knowledge and skill of physicians involved in the cardiology part of the PHE process. 1.6 Research Although there are issues of debate regarding wide-scale mandatory use of the ECG for athlete screening16,24, there is sufficient evidence to justify a staged implementation with evaluation to the of the test in a of sporting implementation provide a control group to in outcome ECG screened and unscreened Finally, the mortality effects of a screening in need to be in other ethnic populations the underlying disease conditions may from those seen in The sport organizations and scientific sport societies should encourage that could current knowledge and data regarding the and to SCD in competitive athletes. MEDICAL Introduction To the main of the PHE have been to screen elite athletes for possible risk for sudden cardiovascular musculoskeletal and of the PHE that on medical conditions have to date been to disease, and specific medical of the female However, sports physicians who perform medical on elite athletes, as well as of the medical team that athletes to the Olympic Games and other sports medical conditions that are and are of a In it was that of the athletes seen at the medical at the Olympic Games were for related In in the athlete medical during the Olympic Games, medical respiratory were more than in 2 other of the medical in a team during 2 Olympic Games were It is important to that the of medical in these 2 studies was Therefore, medical conditions in other than the cardiovascular system are common in elite athletes. These conditions can before during of training in for and after competitions. In 2 the of medical conditions in athletes during the Olympic Games has been These data indicate that medical other than cardiovascular are common in elite athletes, these conditions have not attention in a PHE. A of medical conditions can in athletes a number of medical and these can be identified during a Finally, a number of these conditions are and can be Therefore, clearance for sports participation when athletes from these conditions is an ongoing and ongoing monitoring and 1: of all of at the Olympic Games in a That be in a purpose of this is to (1) review the evidence for including in the PHE that on medical (2) in the medical history, physical examination and that could be in a PHE to identify significant medical and (3) suggest future for in this Evidence There is data available on the of assessment for medical conditions in a PHE. Evidence for the of screening tests to identify medical conditions in a PHE is limited to expert and case However, the identification of some medical conditions is in the medical history, physical examination and of of existing PHE The evidence for including screening to identify medical conditions in a will be reviewed The for including an assessment of the system in a PHE is that respiratory symptoms that are suggestive of are common in At the time of a PHE, these symptoms can be identified, and the clinical together with tests can be used to confirm the of The of in athletes is high and from in sports to in during a PHE, respiratory conditions other than that can also to respiratory symptoms in athletes can be The main for including routine assessment during a PHE is based on the than of iron in athletes, female An additional is to determine if the athlete has or and to identify other illnesses such as It is that testing has been as a tool for blood as The of a on routine screening is in compared with male The for including in the PHE to identify in elite athletes is based on the that (1) than of conditions has been in elite (2) athletes could be to a of at different take and (3) and chronic could in morbidity and also reduce athletic and The to disease in a PHE is based on a number of important it is that during training and following there is evidence of in athletes that could to is a to participation in sports because of the risk of injury and in some cases increased risk of of the to the PHE an opportunity to whether an athlete has been including those that may be associated with to specific There are a number of illnesses that could be when a PHE and these have been reviewed and The for including the and assessment in a PHE is based on the high incidence medical during that are related to this system in elite athletes the common illnesses in the system of athletes are and respiratory The for including this of conditions in PHE has been The for including a assessment in the PHE is that are common in participation in sports may athletes to conditions and there is a risk of of conditions during Therefore, clearance to may have to be if athletes from some The for including an assessment of the system in the PHE is not based on However, it is known that (1) and disease can be and (2) conditions such as asymptomatic and are when screening in athletes is Although these conditions may not be they do require further evaluation to exclude underlying disease. The for including an assessment of the system in the PHE is that symptoms are common in athletes endurance during sports of significant underlying disease is important in athletes, those that from symptoms during conditions are also when with athletes to The for including assessment of conditions in the PHE of athletes is that conditions are and can include a of different conditions such as and although can in including athletes. It has been that the PHE should include screening for the risk factors of in young The for routine to determine if elite athletes have underlying and disease is (1) that these conditions do in elite (2) of the more common conditions in elite athletes is diabetes mellitus Olympic athletes therapeutic use for the use of in the Olympic and (3) elite athletes with existing and disease may require and because they may use could control The for including assessment in the PHE is that visual have been in of athletes undergoing a less common conditions can also be Proposal for of the PHE of medical conditions during a PHE include an appropriate medical history A physical examination and selected should